Summary
Regular screening mammographies and increasing knowledge of high-risk groups have resulted in an improvement in the rate of detection of smaller malignant lesions. However, uncertain minimal mammographic features frequently require further costly and often uncomfortable investigation, including repeat radiological controls or surgical procedures, before cancerous lesions can be identified. Placental isoferritin (p43), a protein with immunosuppressive effects, has been detected on the surface of lymphocytes taken from peripheral blood in patients with breast cancer. In this study we evaluated the sensitivity and specificity of the expression of p43-positive lymphocytes as a marker in early stage breast cancer and also investigated its expression on T-cell subpopulations. The presence of p43-positive lymphocytes was investigated using the monoclonal antibody CM-H-9 and flow cytometry in 76 women with controversial, non-palpable mammographic findings who were undergoing surgical biopsy. Patients with early breast cancer (n = 48) had significantly higher p43-positive cell values (median 3.83%, range 0.98–19.4) than patients with benign lumps (n = 28, median 1.43%, range 0.17–3.7) or controls (n = 22, median 1.3%, range 0.4–1.87) (P < 0.0001). At a cut-off level of 2% p43-positive cells a sensitivity of 91.7% and a specificity of 89.3% for detection of breast cancer could be reached. While the median ratio of total CD4+/CD8+ cells was 2.6, a ratio of 1.3 was found for the p43-positive subpopulation (P < 0.001), thus indicating a significant link between p43 and CD8+ cells. The determination of p43-positive lymphocytes in peripheral blood could serve as an additional diagnostic tool in patients with controversial mammographic findings and could also reduce the need for cost-intensive and often uncomfortable management of these patients.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arnesson, L., Vitak, B., Manson, J., Fagerberg, G. & Smeds, S. (1995). Diagnostic outcome of repeated mammography screening. World J Surg 19: 372–377.
Bach, F., Geller, R., Nelson, P., Panzer, S., Gromo, G., Benfield, M., Inverardi, L., Podack, E., Witson, J. & Houchins, J. (1989). A ‘minimal signal-stepwise activation’ analysis of functional maturation of T lymphocytes. Immunol Rev 111: 35–57.
Bilik, R., Mor, C., Hazaz, B. & Moroz, C. (1989). Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer. Cancer Immunol Immunother 28: 143–147.
Black, W., Nease, R. & Tosteson, A. (1995). Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 87: 720–731.
Bloom, H. & Richardson, W. (1957). Histological grading and prognosis in breast cancer. Br J Cancer 11: 259–364.
Ciatto, S., Rosselli-Del, T. & Zappa, M. (1995). The detectability of breast cancer by screening mammography. Br J Cancer 71: 337–339.
Fargion, S., Fracanzani, A., Bando, B., Arosio, P., Levi, S. & Fiorelli, G. (1991). Specific binding sites of H-ferritin on human lymphocytes modulation during cellular proliferation and potential implication in cell growth control. Blood 78: 1056–1061.
Flanagan, F., Dehdashti, F. & Siegel, B. (1998). PET in breast cancer. Semin Nucl Med 28: 290–302.
Friedrich, M. (1998). MRI of the breast: state of the art. Eur Radiol 8: 707–725.
Garty, B., Kaminsky, E. & Moroz, C. (1995). The immunosuppressive human placental ferritin subunit p43 is produced by activated CD4+ lymphocytes. Clin Diagn Lab Immunol 2: 225–226.
Harris, R. & Leininger, L. (1995). Clinical strategies for breast cancer screening: weighing and using the evidence. Ann Intern Med 122: 539–547.
Hiatt, R. & Pasick, R. (1996). Unsolved problems in early breast cancer detection: focus on the underserved. Breast Cancer Res Treat 40: 37–51.
Leitch, A. (1995). Controversies in breast cancer screening. Cancer 76: 2064–2069.
Lidbrink, E., Elfving, J., Frisell, J. & Jonsson, E. (1996). Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. Br Med J 312: 273–276.
Maes, R., Dronkers, D., Hendriks, J., Thijssen, M. & Nab, H. (1997). Do non-specific minimal signs in a biennial mammographic breast cancer screening programme need further diagnostic assessment?. Br J Radiol 70: 34–38.
Maymon, R. & Moroz, C. (1996). Placental isoferritin: a new biomarker from conception to delivery. Br J Obstet Gynaecol 103: 301–305.
Meuer, S., Cooper, D., Hodgdon, J., Hussey, R., Fitzgerald, K., Schlossman, S. & Reinherz, E. (1983). Identification of the receptor for antigen and major histocompatibility complex on human inducer T lymphocytes. Science 222: 1239–1242.
Moroz, C., Giler, S., Kupfer, B. & Urca, I. (1977). Lymphocytes bearing surface ferritin in patients with Hodgkin’s disease and breast cancer. N Engl J Med 298: 1175–1176.
Moroz, C., Kupfer, B., Twig, S. & Parhami, S. (1985). Preperation and characterization of monoclonal antibodies specific to placenta ferritin. Clin Chim Acta 148: 111–118.
Moroz, C., Kahn, M., Ron, E., Luria, H. & Chaimoff, C. (1989a). The use of oncofetal ferritin-bearing lymphocytes as a marker for the screening, diagnosis, and follow-up of patients with early breast malignancy screening of 3400 women. Cancer 64: 691–697.
Moroz, C., Misrock, S. & Siegal, F. (1989b). Isoferritins in HIV infection: relation to clinical stage and the pathogenesis of AIDS. AIDS 3: 11–16.
Moroz, C., Chetrit, A., Kahn, M. & Modan, B. (1997). FBL blood test as a predictive marker of breast cancer in high risk women. Med Oncol 14: 39–42.
Panzer, S., Madden, M. & Matsushi, M. (1993). Interaction of IL-1, IL-6 and tumour necrosis factor-alpha (TNF-α) in human T cells activated by murine antigen. Clin Exp Immunol 93: 471–478.
Reinerova, M., Rosen, H., Veselovska, Z., Stierer, M. & Svec, J. (1993). Expression of p43 associated placental isoferritin (PLF) correlates inversely with cell growth in breast cancer cell lines MCF-7 and T47-D. Neoplasma 40: 147–151.
Rosen, H., Moroz, C., Reiner, A., Reinerova, M., Stierer, M., Svec, J., Schemper, M. & Jakesz, R. (1992). Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer. Breast Cancer Res Treat 24: 17–26.
Rosen, H., Stierer, M., Gottlicher, J., Wolf, H., Spoula, H. & Eibl, M. (1993). Determination of placental ferritin-positive peripheral lymphocytes in early stages of breast cancer. Am J Surg 165: 213–217.
Rosen, H., Ausch, C., Reiner, G., Reinerova, M., Svec, J., Tuchler, H., Schiessel, R. & Moroz, C. (1996). Immunosuppression by breast cancer associated p43 – effect of immunomodulators. Breast Cancer Res Treat 41: 171–176.
Sedlak, J., Reinerova, M., Hunakova, L., Ausch, C., Chorvath, B., Rosen, H. & Moroz, C. (1995). Alterations of cell surface antigens induced by placental isoform of ferritin in human carcinoma cell lines. Cancer Lett 94: 101–106.
Sickles, E. (1994). Non-palpable, circumscribed, non-calcified solid breast masses: likelihood of malignancy based on lesion size and age of patient. Radiology 192: 439–443.
Sirota, L., Kupfer, B. & Moroz, C. (1989). Placental isoferritin as a physiological downregulator of cellular immunoreactivity during pregnancy. Clin Exp Immunol 77: 257–262.
Stierer, M., Rosen, H., Weber, R., Hanak, H., Auerbach, L., Spona, J. & Tuchler, H. (1995). A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictor of early recurrence in primary breast cancer. Breast Cancer Res Treat 36: 11–21.
Tabar, L., Fagerberg, G., Chen, H., Duffy, S., Smart, C., Gad, A. & Smith, R. (1995). Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 75: 2507–2517.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Auerbach, L., Hellan, M., Stierer, M. et al. Identification of women with early breast cancer by analysis of p43-positive lymphocytes. Br J Cancer 80, 874–878 (1999). https://doi.org/10.1038/sj.bjc.6690434
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690434